A study to learn how safe the study treatment actinium-225-macropa-pelgifatamab (BAY3546828) is, how it affects the body, how it moves into, through and out of the body, and about its anticancer activity in men with advanced metastatic castration-resistant prostate cancer (mCRPC)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502623-22-00

Acronym

22143

Enrollment

Registered

2023-07-12

Start date

2023-09-18

Completion date

Unknown

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic castration-resistant prostate cancer

None listed

Sex/Gender

Male

Age

18 Years to No maximum

Finland, Italy, Netherlands, Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026